Please login to the form below

Not currently logged in
Email:
Password:

Multipharma launches Inceptua Medicines Access

The group will be split into three sub-divisions

InceptuaMultipharma has launched Inceptua Medicines Access, a speciality business unit that offers access to pre-approval and unlicensed medicines.

The Luxembourg-based drug sourcing group’s new business will be split into three divisions that cover pre-approval access programmes, sourcing and supplying unlicensed medicines and strategy support services.

Peter Krantz, chief executive officer of Multipharma, said: “The establishment of Inceptua Medicines Access is the logical next step in the expansion of Multipharma, and perfectly complements the existing services supporting clinical trials of comparator sourcing, strategic planning, global depot solutions and clinical manufacturing.

“With this new addition Multipharma is poised to become a major global provider in the clinical trial services, pre-approval and unlicensed medicines space.”

All Inceptua three divisions will harness “state-of-the-art technologies” seeks to deliver medicines and investigational treatments to patients in areas that lack these facilities.

Mark Corbett, executive vice president of Inceptua Medicines Access, said: “The sector has not adapted nor kept pace with the needs of the biopharmaceutical industry, healthcare professionals and their patients worldwide.

“Current demand combined with a complex and dynamic regulatory and political landscape means we need a new way of thinking about ethical and compliant access to pre-approval and unlicensed medicines.

“We want to provide our clients and customers with a best-in-class service that makes us the go-to global provider for pre-approval and unlicensed medicines.”

Article by
Gemma Jones

16th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics